2.50

4.94% -0.13

After Hours: 2.55 0.05 +2.00%

Nexalin Technology Inc (NXL)

Overview News Price History Financials Discussions Forecast

Nexalin Technology Inc stock is traded at $2.50, with a volume of 195.75K. It is down -4.94% in the last 24 hours and down -8.09% over the past month. Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Previous Close:

$2.63

Open:

$2.63

24h Volume:

195.75K

Relative Volume:

0.43

Market Cap:

$33.26M

Revenue:

$128.60K

Net Income/Loss:

$-4.60M

P/E Ratio:

-3.9683

EPS:

-0.63

Net Cash Flow:

$-3.74M

1W Performance:

-27.75%

1M Performance:

-8.09%

6M Performance:

+159.46%

1Y Performance:

+701.28%

1-Day Range:

$2.41

$2.70

1-Week Range:

$2.41

$3.5399

52-Week Range:

$0.302

$4.4899

Nexalin Technology Inc Stock (NXL) Company Profile

Name

Nexalin Technology Inc

Sector

Healthcare (1167)

Industry

Medical Devices (155)

Phone

(832) 260-0222

Address

1776 YORKTOWN, HOUSTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NXL's Discussions on Twitter

Compare NXL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NXL Nexalin Technology Inc	2.50	33.26M	128.60K	-4.60M	-3.74M	-0.63
ABT Abbott Laboratories	135.82	235.56B	41.95B	13.40B	6.35B	7.65
SYK Stryker Corp	390.30	148.93B	22.60B	2.99B	3.49B	7.76
BSX Boston Scientific Corp	100.72	148.64B	16.75B	1.85B	2.37B	1.25
MDT Medtronic Plc	90.48	116.11B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	71.45	42.14B	5.72B	4.17B	490.10M	6.97

Nexalin Technology Inc Stock (NXL) Latest News

Feb 19, 2025

Nexalin Secures UCSD IRB Approval For Use Of HALO Clarity In PTSD And MTBI Clinical Studies - Nasdaq

Feb 19, 2025

Feb 18, 2025

Nexalin Technology Announces UCSD IRB Approval for use of - GlobeNewswire

Feb 18, 2025

Nexalin Technology Announces UCSD IRB Approval For Use Of HALO Clarity In Clinical Trials For mTBI And PTSD Treatment - Marketscreener.com

Feb 18, 2025

Nexalin Technology Says Halo Clarity Headset Clinical Testing Gets UCSD Institutional Review Board Approval - Marketscreener.com

Feb 18, 2025

Nexalin Technology, Inc. Receives IRB Approval for UCSD Clinical Trials of HALO™ Clarity Headset in Treating mTBI and PTSD - Nasdaq

Feb 18, 2025

Revolutionary Brain Treatment Device Enters Military PTSD Trials at UCSDPotential Breakthrough for Veterans - StockTitan

Feb 18, 2025

Feb 16, 2025

10,000 Shares in Nexalin Technology, Inc. (NASDAQ:NXL) Bought by Kingsview Wealth Management LLC - Defense World

Feb 16, 2025

Feb 13, 2025

Nexalin Technology Inc [NASDAQ: NXL] Sees Decrease in Stock Value - Knox Daily

Feb 13, 2025

Feb 11, 2025

Nexalin technology's chief medical officer buys $3,100 in shares - MSN

Feb 11, 2025

Feb 10, 2025

Nexalin Technology Inc’s latest rating changes from various analysts - Knox Daily

Feb 10, 2025

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition - GlobeNewswire

Feb 10, 2025

Nexalin Technology, Inc. Appointed Industry Co-Chair of National Traumatic Brain Injury Registry Coalition - Nasdaq

Feb 10, 2025

Nexalin (NXL) Secures Leadership Role in $4.5B Brain Injury MarketKey Details Investors Should See - StockTitan

Feb 10, 2025

Feb 08, 2025

Nexalin Technology announces effective registration statement - MSN

Feb 08, 2025

Feb 06, 2025

Nexalin Technology announces effective registration statement By Investing.com - Investing.com UK

Feb 06, 2025